Anaplastic Thyroid Cancer Drug Market Trends, Future Outlook, COVID-19 Impact Analysis, Forecast 2023-2029

The global anaplastic thyroid cancer drug market is expected to grow at a CAGR of nearly 6% during the forecast period. Anaplastic thyroid carcinoma is a kind of thyroid cancer that is rare and aggressive. Thyroid cancer accounts for roughly 1-2 percent of all cancers. In May 2018, the combination of tafinlar and mekinist has been approved for the treatment of BRAF V600E mutation-positive ATC that cannot be surgically treated or has spread to other organs. Melanoma and non-small cell lung cancer are two more BRAF V600 mutation-positive metastatic cancers for which Tafinlar and Mekinist have been licensed. This was the first FDA-approved treatment for patients with this aggressive form of thyroid cancer, and it's the third cancer with this specific gene mutation that this drug combination has been approved to treat. This approval illustrates that targeting the same molecular pathway in a variety of disorders is an effective method to speed up the development of therapies that could benefit a larger number of people.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/anaplastic-thyroid-cancer-drug-market

Further, the increasing awareness amongst the population for thyroid cancer, rising medical infrastructure facilities, and innovative technological advancements is contributing to the growth of the market. The number of drugs and formulations are under pipeline information and expected to enter the anaplastic thyroid cancer drug market during the forecast period. The major pipeline drugs are bevacizumab, sorafenib, everolimus, and so on. In addition, the low prevalence of the disease is a restraining factor hampering the growth of the market followed by the rising cost of research & developments, diagnosis, and treatment.

Besides, the rising prevalence of thyroid cancer is further propelling the growth of the market. For Instance, according to the American Society of Clinical Oncology in 2021, an estimated 44,280 adults including 12,150 men and 32,130 women were diagnosed with thyroid cancer in the US with an estimated mortality rate of 2,200 mortalities including 1,050 men and 1,150 women from this disease.

Market Coverage

• The market number available for - 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
Segment Covered-
By Product
Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
Competitive Landscape- including Novartis International AG. Pfizer Inc., Daiichi Sankyo Co. Ltd., and others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Anaplastic Thyroid Cancer Drug Market Report Segment

By Product

• Sorafenib
• Paclitaxel and Pazopanib HCL
• MLN0128
• CA4 P
• Bevacizumab
• Others

A full report of Anaplastic Thyroid Cancer Drug Market is available at: https://www.omrglobal.com/industry-reports/anaplastic-thyroid-cancer-drug-market

Anaplastic Thyroid Cancer Drug Market- Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• Abbott Laboratories
• Baxter International Inc.
• Daiichi Sankyo Co. Ltd
• Eisai Co. Ltd
• Fresenius Kabi
• Genelux Corp.
• Immune Pharmaceuticals Inc.
• Novartis AG
• Pfizer Inc.
• Plexxikon Inc.
• Takeda Pharmaceuticals Inc.
• Teva Pharmaceuticals Industries Ltd.
• Trophogen Inc.

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

Visit More Report at

https://www.asiatimeskorea.com/press-release/%eb%8b%a4%eb%85%84%ec%83%9d-%ec%95%8c%eb%a0%88%eb%a5%b4%ea%b8%b0-%eb%b9%84%ec%97%bc-%ec%95%bd%eb%ac%bc-%ec%8b%9c%ec%9e%a5-%eb%8f%99%ed%96%a5-%ec%97%b0%ea%b5%ac-%eb%b3%b4%ea%b3%a0%ec%84%9c-%ec%84%b1/214465/

https://www.diario-ya.com/regionales/%e8%9b%8b%e7%99%bd%e8%b4%a8%e8%b0%b7%e6%b0%a8%e9%85%b0%e8%83%ba%e4%bc%bd%e7%8e%9b%e8%b0%b7%e6%b0%a8%e9%85%b0%e8%bd%ac%e7%a7%bb%e9%85%b6-2-%e5%b8%82%e5%9c%ba%e8%b6%8b%e5%8a%bf%e3%80%81%e7%a0%94/288342/

https://sportmsr.com/%d8%a7%d9%84%d8%ad%d8%b5%d8%a9-%d8%a7%d9%84%d8%b3%d9%88%d9%82%d9%8a%d8%a9-%d9%84%d8%a3%d9%82%d8%b1%d8%a7%d8%b5-%d8%a7%d9%84%d8%b2%d8%b9%d9%81%d8%b1%d8%a7%d9%86-%d9%81%d9%8a-%d8%b9%d8%a7%d9%85-2022/

https://revistaeconomiasocial.com/2022/12/30/informe-de-mercado-de-medicamentos-para-la-esclerosis-multiple-progresiva-secundaria-2022-por-jugadores-clave-tendencias-tamano-participacion-y-pronostico-2022-2028/

https://monblogapple.com/2022/12/30/rapport-sur-le-marche-de-la-proteine-de-surface-gp-120-2022-par-acteurs-cles-tendances-taille-part-et-previsions-2022-2028/

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.